bmag consulting

  The eSource Clinical Data Market is expanding as pharmaceutical companies, biotechnology companies, CROs, hospitals, and research organizations increasingly adopt electronic technologies for collecting and managing clinical trial data. BMAG Consulting estimates that the market reached USD 1.62 billion in 2025 and is projected to reach USD 3.94 billion by 2032 , growing at a 13.5% CAGR from 2025 to 2032 . What Is eSource Clinical Data? eSource clinical data refers to information captured electronically at its original source for use in clinical research. Instead of collecting information on paper and subsequently transcribing it into an electronic clinical database, eSource technologies can allow information to enter the digital research workflow closer to the point of generation. Examples include: Electronic Health Records ePRO/eCOA devices Wearable devices Connected sensors Direct data-entry systems Telehealth-generated information Laboratory and diagnostic data feeds Key eSou...

  The digital transformation of healthcare is changing how consumers and healthcare professionals approach nutrition management. Personalized nutrition software is emerging as an important category within digital health by combining nutrition information with individual health, lifestyle, biomarker, and behavioral data. According to BMAG Consulting, the Personalized Nutrition Software Market was valued at USD 1.15 billion in 2025 and is expected to reach USD 3.85 billion by 2032, growing at a CAGR of 18.9% during 2025–2032. What Is Personalized Nutrition Software? Personalized nutrition software refers to digital platforms and services that provide individualized nutrition guidance. Depending on the platform, personalization may incorporate: Dietary information Lifestyle inputs Activity metrics Genetic profiles Gut microbiome information Continuous glucose monitoring Blood biomarkers Health and clinical information Consumer applications can provide meal recommendations, food scorin...

  New Delhi, India – September 21, 2026: BMAG Consulting has published a new report on the global Adaptive Clinical Trial Software Market , highlighting technological developments, adoption patterns, and growth opportunities in clinical research software. The market is valued at USD 0.68 billion in 2025 and is forecast to reach USD 1.92 billion by 2032, growing at a CAGR of 16.1%. The increasing adoption of Bayesian statistical approaches, simulation-based planning, and AI-assisted analytics is influencing the development of adaptive clinical research platforms. These technologies can help study teams evaluate trial scenarios and support structured decision-making based on interim evidence. Download Free Sample: https://bmagconsulting.com/sample/adaptive-clinical-trial-software-market KEY INSIGHTS • Bayesian statistical capabilities are becoming an important component of adaptive trial software development. • AI-assisted simulation can help researchers compare multiple trial desi...

Clinical Trial Simulation Market to Reach USD 2.79 Billion by 2032, Driven by AI, Model-Informed Drug Development & Rising Clinical Trial Costs – New Report by BMAG Consulting New Delhi, India – September 10, 2026: BMAG Consulting, a leading market intelligence and business research firm, has released its latest report on the Clinical Trial Simulation Market , highlighting the growing adoption of computational modeling, artificial intelligence, quantitative pharmacology, model-informed drug development, and simulation-based clinical trial design across the global pharmaceutical and biotechnology industries. According to BMAG Consulting, the Clinical Trial Simulation Market was valued at USD 1.54 billion in 2025 and is projected to reach USD 2.79 billion by 2032, expanding at a CAGR of 8.87% during 2025–2032 . North America is expected to maintain its market leadership, while Asia-Pacific is projected to record the fastest growth during the forecast period. Clinical trial simulatio...